Fujifilm to Seek Approval for Covid Drug After Trial Results
This article is for subscribers only.
Fujifilm Holdings Corp. said it would seek regulatory approval in Japan to market an antiviral drug as a treatment for Covid-19, after a trial showed that it helped patients with mild cases test negative for coronavirus faster.
The company plans to apply for approval to expand usage of the drug Avigan as early as October in Japan, it said in a statement Wednesday. The drug, also known by its generic name favipiravir, is currently approved for use in Japan to treat novel influenza. Fujifilm’s stock rose as much as 5% in Tokyo trading after the announcement.